首页> 美国卫生研究院文献>British Journal of Preventive Social Medicine >Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht The Netherlands
【2h】

Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht The Netherlands

机译:为社区中的所有慢性肺病患者接种流感疫苗是否有效?来自荷兰乌得勒支基于一般实践的临床前瞻性队列研究的证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

STUDY OBJECTIVE: There is little information on the potential benefit of immunising all patients with chronic lung disease in the community against influenza. The clinical effectiveness and economic benefit was established of the influenza vaccination programme in a general practice based cohort of adult patients with chronic lung disease followed up during the 1995/96 influenza A epidemic. DESIGN: A prospective cohort study from October 1995 to March 1996. SETTING: The study was undertaken in the Utrecht General Practices Network with six large group practices, covering a total population of approximately 50,000 patients in the Netherlands. PATIENTS: Computerised medical records of 1696 patients with chronic lung disease aged over 18 years with an indication for vaccination according to the Dutch GP guidelines were reviewed. MAIN RESULTS: The overall attack rate of any complication, including all cause death, low respiratory tract infection, and acute cardiac disease was 15%. Exacerbations of lung disease were most frequent (13%). Death, pneumonia, and acute cardiac disease were mainly limited to patients > or = 65 years. No effectiveness of the immunisation programme could be established in patients 18-64 years (n = 1066), after controlling for baseline prognosis in multivariable logistic regression analysis. In vaccinees > or = 65 years (n = 630), the occurrence of any complication was reduced by 50% (95% CI 17, 70%). The economic benefit was estimated at 50 Pounds per elderly vaccinee. CONCLUSIONS: This study suggests that in the Netherlands immunisation of elderly patients with chronic lung disease against influenza is effective and cost-saving, hence these patients should be given high priority. More, preferably experimental, studies are needed to establish whether adult lung patients under 65 years in the community will also benefit from vaccination.  
机译:研究目的:几乎没有关于社区中所有慢性肺病患者进行流感免疫接种的潜在益处的信息。在1995/96年甲型流感流行期间对成年人慢性肺病患者进行随访的一般实践队列中,确定了流感疫苗接种计划的临床有效性和经济效益。设计:一项从1995年10月至1996年3月的前瞻性队列研究。地点:该研究在乌特勒支全科医学网络中进行,共有六大小组实践,覆盖了荷兰大约50,000名患者。患者:根据荷兰GP指南,对1696名18岁以上的慢性肺病患者的计算机病历进行了计算机检查,并有接种疫苗的指征。主要结果:包括所有原因引起的死亡,下呼吸道感染和急性心脏病在内的任何并发症的总发作率为15%。肺部疾病加重最频繁(13%)。死亡,肺炎和急性心脏病主要限于≥65岁的患者。在多变量logistic回归分析中控制基线预后后,无法确定18-64岁(n = 1066)患者的免疫程序是否有效。在≥65岁(n = 630)的疫苗中,任何并发症的发生率降低了50%(95%CI 17,70%)。每位老年被接种者的经济利益估计为50磅。结论:这项研究表明在荷兰对老年慢性肺病患者进行流感疫苗接种是有效且节省成本的,因此应优先考虑这些患者。需要进行更多(最好是实验)研究来确定社区中65岁以下的成年肺部患者是否也将从疫苗接种中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号